Persistent Opioid Exposure in Older Adults with Rheumatic Disease: National Patterns, Disparities, and Cross-Specialty Prescribing
OBJECTIVE: Estimate national prevalence of opioid use, including chronic and high-risk use, among older adults with rheumatic diseases; identify sociodemographic and clinical factors associated with chronic opioid use; and characterize prescribing patterns by clinician specialty in a contemporary Medicare-linked national registry cohort. METHODS: Cross-sectional analysis of the Rheumatology Informatics System for Effectiveness (RISE) registry linked to Medicare Part D (2016-2021). Patients were ≥65 years with qualifying rheumatic diagnoses and continuous Medicare enrollment in 2021. Opioid use was identified from Part D claims. Chronic use was defined as ≥90 days' supply in 2021. High-risk use was assessed using Office of Inspector General indicators. Generalized estimating equations modeled factors associated with chronic opioid use. RESULTS: Among 45,455 patients (mean age 75.8 years; 76.88% women), 43.13% filled ≥1 opioid prescription and 17.93% met criteria for chronic use in 2021. Very high-risk prescribing was rare (<1%). Chronic use was most prevalent in axial spondyloarthritis (axSpA; 26.19%) and least in polymyalgia rheumatica (11.58%). In adjusted analyses, axSpA (OR 1.63, 95% CI 1.35-1.98), fibromyalgia (OR 2.68, 95% CI 2.39-3.00), mood and anxiety disorders, higher comorbidity burden, American Indian/Alaska Native race, and greater socioeconomic deprivation were independently associated with chronic use. Non-rheumatology clinicians wrote most opioid prescriptions (62.60%) and more high-dose prescriptions (≥50 morphine milligram equivalents/day). CONCLUSION: Opioid exposure remains common among Medicare-insured older adults with rheumatic disease, although very high-risk prescribing is rare. Coordinated, guideline-concordant pain management across specialties may help preserve appropriate opioid use for patients who may benefit while reducing avoidable long-term exposure.
Authors
- Jinoos Yazdany (ORCID: https://orcid.org/0000-0002-3508-4094)
- Daniel Ciccarone (ORCID: https://orcid.org/0000-0002-2355-5477)
- Gabriela Schmajuk (ORCID: https://orcid.org/0000-0003-2687-5043)
- Christine Anastasiou (ORCID: https://orcid.org/0000-0002-3074-2529)
- Karen H. Costenbader (ORCID: https://orcid.org/0000-0002-8972-9388)
- Eric M. Roberts (ORCID: https://orcid.org/0000-0002-1379-7931)
Institutions
- San Francisco General Hospital (US)
- San Francisco VA Medical Center (US)
- University of California, San Francisco (US)
- Stanford University (US)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2026-10-15
- DOI
- https://doi.org/10.3899/jrheum.2026-0220
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00